Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05396560

Fecal Immunochemical Test for Post-polypectomy Surveillance to Reduce Unnecessary eNdoscopy

This is an observational study in a clinical setting to estimate the prevalence of advanced colorectal neoplasia (ACN) at colonoscopy in those with a history of low or high risk polyps or a family history of CRC/polyps and to verify the test performance characteristics of FIT in these populations. Using this information, a risk prediction model will be developed to help guide the choice between FIT and colonoscopy in the ongoing surveillance or screening of patients.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–74 year

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Colonoscopy is an effective tool in reducing colorectal cancer (CRC) incidence, however, it is a limited resource that is not without risk. The overall goal of this study is to determine if Fecal Immunochemical Tests (FIT) could be an effective alternative to colonoscopy for the surveillance of patients at increased risk for CRC. The rationale for this project is that colonoscopy is both a more expensive (30-40X) and more limited resource than FIT, which because of its pivotal role in the investigation and management of many gastrointestinal conditions is constantly in demand.

Routine post-polypectomy surveillance is placing a rapidly growing demand on existing colonoscopy resources, driven in part by the rapid expansion of CRC screening programs.(1) Currently, there are not strong contemporary data to guide the use of colonoscopy or alternative tests for the surveillance of patients after the removal of low or high risk polyps, but colonoscopy is routinely recommended by screening guidelines, as historically no other reasonable options existed. Colonoscopy screening is also the default recommendation for individuals with a family history of CRC or polyps.

It is proposed that the highly sensitive and low cost FIT could replace colonoscopy for post-polypectomy surveillance and primary screening in at least some patients and, thereby, reduce costs while improving access to colonoscopy for other patients.

The following knowledge gaps must be filled prior to advocating the use of FIT for post-polypectomy surveillance or primary screening:

  • Contemporary data is lacking on the prevalence of advanced and non-advanced colorectal neoplasia at colonoscopy in a cohort of individuals with well characterized index pathology and/or family history of CRC/polyps.
  • There is limited data on the sensitivity and specificity of FIT for the detection of advanced colorectal neoplasia in these settings.
  • The factors that predict a higher risk of advanced colorectal neoplasia in those undergoing for post-polypectomy surveillance or a family history are unknown.

This is an observational study conducted in a clinical setting to estimate the prevalence of advanced colorectal neoplasia (ACN) at colonoscopy in those with a history of low or high risk polyps or a family history of CRC/polyps and to verify the test performance characteristics of FIT in these populations. Using this information, a risk prediction model will be developed to help guide the choice between FIT and colonoscopy in the ongoing surveillance or screening of patients.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men or women age ≤ 74 years of age.
  • At least one risk factor for CRC that would generally lead to colonoscopy screening:
  • Personal history of low risk polyps
  • Personal history of high risk polyps
  • Family history of CRC or polyps

Exclusion criteria

  • Known acromegaly, cystic fibrosis or high risk profession (firefighter)
  • Referred for colonoscopy due to a positive fecal immunochemical test or CT colonography
  • Known or suspected gene carrier for a familial cancer syndrome.
  • Does not meet medical criteria for colonoscopy at the CCSC.
  • Colonoscopy within the previous 30 months
  • Unable to provide written informed consent or complete questionnaires due to language barrier or other reasons.

Treatment and study plan

Primary outcomes

  1. Advanced Colorectal Neoplasia (ACN) Prevalence

    Time frame: At time of colonoscopy

    ACN: Colorectal cancer or an advanced adenoma (> 1 cm, villous features, high grade dysplasia) or serrated polyp (> 1 cm or any conventional dysplasia).

  2. Fecal Immunochemical Test Sensitivity and Specificity

    Time frame: FIT test to be completed between 3-42 days prior to participant colonoscopy

    Single fecal sample for measurement of hemoglobin using the OC-Sensor FIT. Positive if measured hemoglobin is ≥100 ng/ml (manufacturers recommended cut off).

    Sensitivity = proportion of individuals with at least one ACN who had a positive FIT.

    Specificity = proportion of individuals without advanced lesions who had a negative FIT.

Study contacts

Contact information is provided by the study sponsor or research team.

Robert Hilsden, MD PhD

CONTACT

[email protected]

403-592-5089

Susanna Town, PhD

CONTACT

[email protected]

403-592-5052

Sponsors and collaborators

Lead sponsor

University of Calgary

Other

Registry information

Official study title

Fecal Immunochemical Test for Post-polypectomy Surveillance to Reduce Unnecessary eNdoscopy (FIT2RUN Study)

Acronym: FIT2RUN

Important dates

Study start
2022
Primary completion
2026
Study completion
2027
First posted
May 31, 2022
Registry last updated
May 31, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.